ACTIN Report (research use only)

PATIENT
EXAMPLE-LUNG-01

REPORT DATE
29-Oct-2024

Gender: **Female** | Birth year: **1975** | WHO: **1**

Tumor: **Lung - Adenocarcinoma** | Lesions: **Brain, CNS, Lung** | Stage: **IV**

Summary

Clinical summary

Relevant systemic treatment history	**1/2023-9/2024**	**Osimertinib**
Relevant other oncological history	**None**	
Previous primary tumor	**Skin (neck) squamous cell carcinoma (diagnosed 1/2022, last treatment 1/2022, considered non-active)**	
Relevant non-oncological history	**9/2024**	**Bacterial pneumonia**
	2022	**Rheumatoid arthritis**

Recent molecular results

Hartwig WGS (01-Sep-2024)

Biopsy location	**Lung (purity 50%)**
Molecular tissue of origin prediction	**Lung: Non-small cell: LUAD (98%)**
Tumor mutational load / burden	**TML high (160) / TMB high (14)**
Microsatellite (in)stability	**Stable**
HR status	**Proficient (0)**
High driver mutations	**EGFR L858R, EGFR C797S, KRAS G12D**
Amplified genes	**None**
Deleted genes	**TP53**
Homozygously disrupted genes	**None**
Gene fusions	**MET_MET**
Virus detection	**None**
Potentially actionable events with medium/low driver:	**None**

IHC results

PD-L1: Score > 50%

Example trials that are open and potentially eligible (2 cohorts from 2 trials)

Trial	Cohort	Molecular	Warnings
METC 04 TEDR1	Lung cancer C797S cohort	EGFR C797S	None
METC 02 KAYRAS	Dose expansion - monotherapy - NSCLC	KRAS G12D	Variant(s) KRAS G12D in KRAS but subclonal likelihood of > 50%

Example trials that are open and potentially eligible but currently have no slots available (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose escalation - monotherapy		History of Rheumatoid arthritis, SOC not exhausted: at least platinum doublet remaining

Trial Matching Summary

Example trials and cohorts that may be eligible, but are closed (1)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose expansion - monotherapy		History of Rheumatoid arthritis, SOC not exhausted: at least platinum doublet remaining

Example trials and cohorts that are considered ineligible (2)

Trial	Cohort	Molecular	Ineligibility reasons
METC 02 KAYRAS	Dose expansion - monotherapy - Colorectum	KRAS G12D	No colorectal cancer
METC 03 NO-SEE797ES	Dose escalation - monotherapy		C797S detected in EGFR

Open cohorts with no slots available are shown in grey.

Trial Matching Details

Potentially eligible open trials & cohorts

METC 01

Potentially eligible	**Yes**
Acronym	**IEMOEN**
Title	**Phase I first-in-human study to evaluate safety of IEMOEN, a new PD-L1 inhibitor in advanced solid tumors**

Rule	Reference	Evaluation
I-03	Patient should have exhausted applicable available standard-of-care treatments.	WARN Patient has not exhausted SOC (at least platinum doublet remaining)
E-01	Has an active autoimmune disease that requires systemic treatment and poses a risk according to the investigator.	WARN Patient has history of condition(s) Rheumatoid arthritis, which is indicative of autoimmune disease
E-02	Has hemoglobin below 6 mmol/l	WARN Hemoglobin 8.2 mmol/L exceeds minimum of 6.0 mmol/L, but measurement occurred before 31-Jul-2024
E-03	Has absolute neutrophil count below 1.5 x 10^9/l	UNDETERMINED No measurement found for absolute neutrophil count
I-01	Patients must be ≥18 years old.	PASS Patient is at least 18 years old
I-02	IEMOEN monotherapy is indicated for the treatment of adults with advanced/metastatic solid tumors.	PASS Patient has solid primary tumor Tumor stage IV is considered metastatic

METC 01 - Dose escalation - monotherapy

Cohort ID	**A**
Potentially eligible?	**Yes**
Open for inclusion?	**Yes**
Has slots available?	**No**

METC 01 - Dose expansion - monotherapy

Cohort ID	**B**
Potentially eligible?	**Yes**
Open for inclusion?	**No**
Has slots available?	**No**

METC 02

Potentially eligible	**Yes**
Acronym	**KAYRAS**
Title	**A phase 1/2 trial for first in-human usage of KAYRAS, a new specific KRAS G12D inhibitor in NSCLC and colorectal cancer**

Rule	Reference	Evaluation
I-04	Patient has confirmed KRAS G12D mutation	WARN Variant(s) KRAS G12D in KRAS detected in canonical transcript but subclonal likelihood of > 50%
I-03	ALAT and ASAT should be at most 3*ULN, or at most 5*ULN in case of liver metastases.	UNDETERMINED ASAT and ALAT are not present or cannot be evaluated
I-01	Patient is ≥18 years old.	PASS Patient is at least 18 years old
I-02	KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer.	PASS Tumor stage IV is considered metastatic

METC 02 - Dose expansion - monotherapy - NSCLC

Cohort ID	**A**
Potentially eligible?	**Yes**
Open for inclusion?	**Yes**
Has slots available?	**Yes**

Rule	Reference	Evaluation
I-02	KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer.	PASS Patient has tumor belonging to doid term(s) lung non-small cell carcinoma

METC 02 - Dose expansion - monotherapy - Colorectum

Cohort ID	**B**
Potentially eligible?	**No**
Open for inclusion?	**Yes**
Has slots available?	**Yes**

Rule	Reference	Evaluation
I-02	KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer.	FAIL Patient has no colorectal cancer

METC 04

Potentially eligible	**Yes**
Acronym	**TEDR1**
Title	**TEDR1 Trial: A phase II trial to evaluate efficacy of specific EGFR inhibitors in lung cancer**

Rule	Reference	Evaluation
I-1	Patient is ≥18 years of age.	PASS Patient is at least 18 years old
I-2	Drug 1 as monotherapy is indicated for the treatment of adults with advanced lung cancer.	PASS Patient has tumor belonging to doid term(s) lung cancer Tumor stage IV is considered metastatic
I-3	Patient has a confirmed EGFR C797S mutation	PASS Variant(s) C797S in gene EGFR detected in canonical transcript

METC 04 - Lung cancer C797S cohort

Cohort ID	**A**
Potentially eligible?	**Yes**
Open for inclusion?	**Yes**
Has slots available?	**Yes**

Other trials & cohorts

METC 03

Potentially eligible	No
Acronym	**NO-SEE797ES**
Title	**Phase I trial for development of NO-SEE797ES, a specific inhibitor for EGFR with C797 mutations but not C797S in solid tumors**

Rule	Reference	Evaluation
I-03	Tumors should contain EGFR C797 but not EGFR C797S mutation.	FAIL Variant(s) C797S in gene EGFR detected in canonical transcript

METC 03 - Dose escalation - monotherapy

Cohort ID	**A**
Potentially eligible?	No
Open for inclusion?	**Yes**
Has slots available?	**Yes**